SCHEMBL4079296

SCHEMBL4079296

CC(C)C[SiH](CC(C)C)c1ccc(CC(=O)ON2C(=O)CCC2=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.39
KMT2A Q03164 2/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 2/20 0.35
CYP19A1 P11511 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
FAAH O00519 1/20 0.32
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
MGLL Q99685 1/20 0.32
LMNA P02545 1/20 0.32
SLC1A2 P43004 1/20 0.32
POLB P06746 1/20 0.31
ENPP2 Q13822 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4082771 0.85 MAPK1 (0.39) MAPK1KMT2AHPGDTSHRCYP19A1
SCHEMBL22650192 0.83 MAPK1 (0.42) MAPK1KMT2AHPGDTSHRSMN1; SMN2
SCHEMBL4079583 0.82 ALDH1A1 (0.36) MAPK1KMT2AHPGDTSHRALDH1A1
SCHEMBL499428 0.82 KMT2A (0.46) MAPK1KMT2AHPGDTSHRSMN1; SMN2
SCHEMBL12018040 0.81 CYP19A1 (0.40) MAPK1KMT2AHPGDTSHRCYP19A1
SCHEMBL17356716 0.78 KMT2A (0.41) MAPK1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL15896085 0.78 KMT2A (0.44) MAPK1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL25519725 0.77 MAPK1 (0.39) MAPK1KMT2AHPGDTSHRSMN1; SMN2
SCHEMBL4083706 0.76 MAPK1 (0.37) MAPK1KMT2AHPGDTSHRCYP19A1
SCHEMBL14229269 0.76 MAPK1 (0.37) MAPK1KMT2AHPGDTSHRCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074135-A2 SILICON DERIVATIVES FOR PET IMAGING Bayer Schering Pharma AG (DE) 2009-07-01 EP claimed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US claimed
EP-1970064-A1 Silicon-derivatives for pet-imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-17 EP claimed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP claimed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO claimed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP claimed
EP-2074135-A2 SILICON DERIVATIVES FOR PET IMAGING Bayer Schering Pharma AG (DE) 2009-07-01 EP disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
EP-1970064-A1 Silicon-derivatives for pet-imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-17 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035215-A1 RADIOFLUORINATION AFF2, AFF1, NUTF2 MAPK1 2960/4885KMT2A 2045/4885HPGD 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.